The British Journal of Clinical Pharmacology

Volume 21
1986

Published for
The British Pharmacological Society by
Blackwell Scientific Publications

© 1986 Blackwell Scientific Publications
Osney Mead, Oxford OX2 0EL
8 John Street, London WC1N 2ES
23 Ainslie Place, Edinburgh EH3 6AJ
52 Beacon Street, Boston, Mass. 02108, USA
667 Lytton Avenue, Palo Alto, Calif. 94301, USA
107 Barry Street, Carlton, Victoria 3053, Australia

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Scientific Publications for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $02.00 per copy is paid directly to CCC, 27 Congress Street, Salem, MA 01970, USA. 0306-5251/86 $02.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by Oxprint Ltd, Oxford*
Printed in Great Britain
at the University Press, Cambridge

*Except for Supplement 1 to Volume 21,
which was typeset from disc by
Getset (Bowden Typesetting Services) Ltd,
Eynsham, Oxford

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

Contents

Number 1, January 1986

Papers

1 Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long acting rifamycin derivative: *D. Vital Durand, C. Hampden, A. R. Boobis, B. K. Park & D. S. Davies*

9 D-glucaric acid excretion in critical care patients—comparison to 6β-hydroxycortisol excretion and serum γ-glutamyltranspeptidase activity and relation to multiple drug therapy: *G. Heinemeyer, I. Roots, P. Lestau, H.-R. Klaiber & R. Dennhardt*

19 The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man: *J. T. Lahtela, B. Gachalyi, S. Eksymä, A. Hämäläinen & E. A. Sotaniemi*

27 Action of compounds with effective *in vivo* mineralocorticoid activity on ion transport in leucocytes: *D. N. Baron & R. J. Green*

35 Experimental pain induced by electrical and thermal stimulation of the skin in healthy man: sensitivity to 75 and 150 mg diclofenac sodium in comparison with codeine and placebo: *G. Stacher, H. Steinringer, S. Scheider, G. Mittelbach, S. Winklehner & G. Gaupmann*

45 Relationship between plasma concentrations and cardiac β-adrenoceptor blockade—a study with oral and intravenous bopindolol: *W. H. Aellig, E. Nüesch, G. Engel, J. Grevel, W. Niederberger & J. Rosenthaler*

53 Studies with fenoldopam, a dopamine receptor DA_1 agonist, in essential hypertension: *J. N. Harvey, D. P. Worth, J. Brown & M. R. Lee*

63 Pharmacokinetics of enalapril in normal subjects and patients with renal impairment: *J. G. Kelly, G. Doyle, J. Donohue, M. Laher, M. J. Vandenburg, W. J. C. Currie & W. D. Cooper*

Short reports

71 Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose: *L. E. Domino, S. E. Domino & M. S. Stockstill*

75 Inhibition of antipyrine elimination by disulfiram and cimetidine: the effect of concomitant administration: *S. Loft, J. Sonne, H. Pilsgard, M. Døssing & H. Enghusen Poulsen*

Letter to the Editors

79 Quantifying ease of swallowing: a comparison of a new lozenge formulation for paracetamol and placebo tablets: *S. Mahadeva, A. Herxheimer & S. J. Corne*

Proceedings

81 Proceedings of the British Pharmacological Society (University of Edinburgh, 9–11 September 1985)

Number 2, February 1986

Papers

125 *In vitro* immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells: *E. Langhoff & K. Olgaard*

131 Effects of locally administered anticholinesterase agents on the secretory response of human eccrine sweat glands to acetylcholine and carbachol: *J. Longmore, B. Jani, C. M. Bradshaw & E. Szabadi*

137 Haemodynamic effects of vasodilating drugs on the common carotid and brachial circulations of patients with essential hypertension: *J. D. Bouthier, M. E. Safar, A. Benetos, A. Ch. Simon, J. A. Levenson & Ch. M. Hugues*

143 Effect of captopril on bradykinin inactivation by human foetal placental circulation: *R. Soares de Moura & N. Solano Vale*

149 The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias: *A. H. Thomson, G. Murdoch, A. Pottage, A. W. Kelman, B. Whiting & W. S. Hillis*

155 Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis: *L. Aarons, R. Salisbury, M. Alam-Siddiqi, L. Taylor & D. M. Grennan*

165 Inability of ibuprofen to alter single dose phenytoin disposition: *K. A. Bachmann, J. I. Schwartz, R. B. Forney Jr. L. Jauregui & T. J. Sullivan*

171 Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers: *J. Sjovall, G. Alván & B. Huitfeldt*

183 The dose-dependent systematic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone: *F. J. Frey, M. K. Ruegsegger & B. M. Frey*

191 Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity: *M. -J. Ramond, E. Comoy & D. Lebrec*

197 Kinetic and dynamic interaction of brotizolam and ethanol: *J. M. Scavone, D. J. Greenblatt, J. S. Harmatz & R. I. Shader*

205 Hypnotic activity of an imidazo-pyridine (zolpidem): *A. N. Nicholson & P. A. Pascoe*
213 Subclinical impairment of colour vision in patients receiving ethambutol: *P. H. Joubert, J. G. Strobele, C. W. Ogle & C. A. van der Merwe*
217 A comparison of the clinical and bronchodilating effects of plain and slow-release tablets of terbutaline at steady state: *R. Pauwels, W. Elinck, H. Lamont, M. van der Straeten & K. Ljungholm*

Short reports
223 A correlation between serum mebendazole concentrations and the aminopyrine breath test: implications in the treatment of hydatid disease: *A. Bekhti, J. Pirotte & R. Woestenborghs*
227 Intravenous adenosine in the treatment of supraventricular tachycardia: a dose-ranging study and interaction with dipyridamole: *A. H. Watt, M. S. Bernard, J. Webster, S. L. Passani M. R. Stephens & P. A. Routledge*
231 Plasma concentrations of sodium cromoglycate given by nebulisation and metered dose inhalers in patients with exercise-induced asthma: relationship to protective effect: *K. R. Patel, W. M. Tullett, M. G. Neale, R. T. Wall & K. M. Tan*
234 Bronchodilator activity of a new inhaled β_2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma: *K. R. Patel*

Letters to the Editors
239 Arbaprostil (15(R)-15-methyl PGE_2): lack of effect on theophylline metabolism: *S. B. Reele, A. Euler, J. McEvers & C. Metzler*
241 Hypotension in response to iloprost, a prostacyclin analogue: *J. W. Upward, H. A. Strong, C. F. George, B. C. Ogilvie, V. Challenor & N. Conway*
243 Fenoldopam: effect on aldosterone secretion: *A. G. Dupont, P. Vanderniepen, A. Volckaert, J. Smitz, A. C. Vansteirteghem & R. O. Six*
245 The warfarin–cimetidine interaction: stereochemical considerations: *S. Toon, K. J. Hopkins, F. M. Garstang, B. Diquet, T. S. Gill & M. Rowland*

Number 3, March 1986

Papers
249 Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced β-adrenoceptor responses in man: *T. H. Pringle, P. C. O'Connor, A. J. McNeill, M. B. Finch, J. G. Riddell & R. G. Shanks*
259 The cardiovascular effects of xamoterol, a β_1-adrenoceptor partial agonist, in healthy volunteers at rest: *T. Hashimoto, A. Shiina, T. Toyooka, S. Hosoda & K. Kondo*
267 Does 2-mercaptoethane sulphonate (Mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? *In vitro* studies: *S. A. Al-Safi & J. L. Maddocks*
271 Stereoselective interaction between the R enantiomer of warfarin and cimetidine: *I. A. Choonara, S. Cholerton, B. P. Haynes, A. M. Breckenridge & B. K. Park*
279 Pharmacokinetics of ranitidine in critically ill patients: *K. F. Ilett, R. L. Nation, R. Tjokrostetio, W. R. Thompson, T. E. Oh & P. D. Cameron*
289 Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins: *B. K. Park, I. A. Choonara, B. P. Haynes, A. M. Breckenridge, R. G. Malia & F. E. Preston*
295 Gastrointestinal side effects after intravenous erythromycin lactobionate: *K. M. Downey & D. M. Chaput de Saintonge*
301 The effect of intra-articular steroids on plasma salicylate concentrations: *J. Edelman, J. M. Potter & L. P. Hackett*
309 Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man: *B. Rosenkranz, C. Fischer, C. O. Meese & J. C. Frölich*

Short reports
319 Dose independent pharmacokinetics of mexiletine in healthy volunteers: *T. H. Pringle, J. Fox, A. J. McNeill, C. D. Kinney, J. Liddle, D. W. G. Harron & R. G. Shanks*
322 The effect of chloroquine on paracetamol disposition and kinetics: *K. K. Adjepon-Yamoah, N. M. Woolhouse & L. F. Prescott*
325 Tobramycin pharmacokinetics in very low birth weight infants: *M. C. Nahata, D. A. Powell, D. E. Durrell & M. A. Miller*
328 Inhibition of human liver cytochrome P-450 by omeprazole: *J. C. Jensen & R. Gugler*
331 The effect of vehicle on the oral absorption of cyclosporin: *A. Johnston, J. T. Marsden, K. K. Hla, J. A. Henry & D. W. Holt*
334 The plasma protein binding of metoclopramide in health and renal disease: *D. Webb, D. C. Buss, R. Fifield, D. N. Bateman & P. A. Routledge*

Letters to the Editors
337 Effect of a high protein meal on the bioavailability of verapamil: *B. G. Woodcock, N. Kraemer & N. Rietbrock*
338 The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects: *A. A. Ajayi & J. L. Reid*
340 Enalapril and baroreflex function in normotensive subjects: *J. F. Giudicelli & A. Berdeaux*

Number 4, April 1986

Papers

341 Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat: *N. Hockings, A. A. Ajayi & J. L. Reid*

349 Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat: *A. A. Ajayi, N. Hockings & J. L. Reid*

359 Comparison of the acute vascular effects of frusemide and bumetanide: *G. D. Johnston, D. P. Nicholls, G. B. Kondowe & M. B. Finch*

365 Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid: *A. McAllister, H. Mosberg, J. A. Settlage & J. A. Steiner*

371 Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros® oxprenolol delivery system in young normotensive and elderly hypertensive subjects: *I. D. Bradbrook, M. Babiker, P. Crome, H. C. Gillies, P. J. Morrison, H. J. Rogers & P. Shotton*

377 Slow release nifedipine and atenolol as initial treatment in blacks with malignant hypertension: *C. G. Isles, A. O. C. Johnson & F. J. Milne*

385 The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers: *N. M. G. Debbas, S. H. D. Jackson, K. Shah, S. M. L. Abrams, A. Johnston & P. Turner*

389 The interaction between i.v. theophylline and chronic oral dosing with slow-release nifedipine in volunteers: *S. H. D. Jackson, K. Shah, N. M. G. Debbas, A. Johnston, C. A. Peverel-Cooper & P. Turner*

393 The haemodynamic and myocardial effects of dopexamine: a new β_2-adrenoceptor and dopaminergic agonist: *B. E. Jaski, W. Wijns, R. Foulds & P. W. Serruys*

401 Racial differences in drug responses—a comparative study of trimazosin and α_1-adrenoceptor responses in normotensive Caucasians and West Africans: *J. Vincent, H. L. Elliott, P. A. Meredith & J. L. Reid*

409 Quantitation of dose and concentration–effect relationships for fenclofenac in rheumatoid arthritis: *F. M. Dunagan, P. E. McGill, A. W. Kelman & B. Whiting*

417 The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension: *P. P. Koopmans, Th. Thien, C. M. G. Thomas, R. J. Van den Berg & F. W. J. Gribnau*

425 Prolonged midazolam elimination half-life: *J. W. Dundee, P. S. Collier, R. J. T. Carlisle & K. W. Harper*

431 Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease: *J. L. Shaffer, A. Kershaw & J. B. Houston*

437 Trends in the development of new medicines by UK-owned pharmaceutical companies (1964–1980): *R. A. Prentis & S. R. Walker*

445 Protective effect of theophylline on histamine-induced bronchoconstriction in asthmatic children: *S. Levene & S. A. McKenzie*

Short reports

451 Potentiation of the adverse effects of intravenous terbutaline by oral theophylline: *S. Rolf Smith & M. J. Kendall*

454 Effect of allopurinol on caffeine disposition in man: *D. M. Grant, B. K. Tang, M. E. Campbell & W. Kalow*

459 Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. *L. D. Lewis, A. S. E. Fowle, S. B. Bittiner, A. Bye & P. E. T. Isaacs*

Letters to the Editors

463 Comment on a letter on the elimination of treatment predictability: *D. A. Thompson*

463 Reply to Dr Thompson on the elimination of treatment predictability: *A. L. Jones, S. L. Grainger & S. E. Smith*

Number 5, May 1986

Papers

465 Debrisoquine oxidation in an Australian population: *G. F. Peart, J. Boutagy & G. M. Shenfield*

473 A simple borohydride/GC method for measuring sparteine metabolites in man: *T. Inaba, A. Vinks & S. V. Otton*

481 Stereoselective disposition of mexiletine in man: *O. Grech-Belanger, J. Turgeon & M. Gilbert*

489 Enalapril in moderate to severe hypertension: a comparison with atenolol: *J. Webster, J. C. Petrie, O. J. Robb, J. Trafford, J. Burgess, P. J. Richardson, C. Davidson, G. Fairhurst, M. J. Vandenburg, W. D. Cooper, S. M. Arr & G. Kimber*

497 Domperidone treatment in man inhibits the fall in plasma renin activity induced by intravenous γ-L-glutamyl-L-dopa: *D. P. Worth, J. N. Harvey, J. Brown, A. Worral & M. R. Lee*

503 A comparison of the gastric and central nervous system effects of two substituted benzamides in normal volunteers: *G. R. McClelland & J. A. Sutton*

Short reports

511 Pharmacokinetics of antipyrine in epileptic patients: *E. M. Rimmer, P. A. Routledge, L. M. Tsanaclis & A. Richens*

515 Cimetidine absorption in humans during sucralfate coadministration: *R. D'Angio, M. Mayersohn, K. A. Conrad & M. Bliss*

521 The pharmacokinetics of doxazosin in elderly normotensives: *J. Vincent, P. A. Meredith, H. L. Elliott & J. L. Reid*

525 Plasma amiodarone concentrations during intravenous infusion: *A. H. Watt, A. Hutchings, M. R. Stephens & P. A. Routledge*

529 A comparison of the pharmacokinetics of propranolol in obese and normal volunteers: *S. L. Bowman, S. A. Hudson, G. Simpson, J. F. Munro & J. A. Clements*

533 Transient bradycardia and subsequent sinus tachycardia produced by intravenous adenosine in healthy adult subjects: *A. H. Watt & P. A. Routledge*

537 Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery: *J. L. Halperin, B. P. Mindich, E. B. Rothlauf, R. F. Reder, R. S. Litwak & J. Kupersmith*

543 Captopril and opiate antagonism in essential hypertension: *A. A. Ajayi, P. C. Rubin & J. L. Reid*

Letters to the Editors

547 No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama: *T. D. Arias, L. F. Jorge & T. Inaba*

548 Medical research on normal volunteers: *J. M. Royle & E. S. Snell*

550 Interaction between cyclosporin A and phenobarbitone: *H. Carstensen, N. Jacobsen & H. Dieperink*

552 The detection of amodiaquine in blood after oral administration: *P. A. Winstanley, G. Edwards, M. L'E. Orme & A. M. Breckenridge*

553 Disopyramide and breast feeding: *K. Hoppu, P. J. Neuvonen & T. Korte*

554 Verapamil pharmacokinetics: *P. A. Meredith, H. L. Elliott & J. L. Reid*

555 Verapamil pharmacokinetics: *J. B. Schwartz, D. R. Abernethy & J. Egan*

Proceedings

557 Proceedings of the British Pharmacological Society (University of London, 18–20 December 1985)

Number 6, June 1986

Papers

621 Felodipine *vs* hydralazine: a controlled trial as a third line therapy in hypertension: *Co-operative Study Group*

627 Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol: *R. Vandongen, B. Margetts, N. Deklerk, L. J. Beilin & P. Rogers*

633 The effect of 8 weeks' treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension: *P. L. Katzman, U. L. Hulthén & B. Hökfelt*

641 Differential effects of atenolol and enalapril on memory during treatment for essential hypertension: *I. Lichter, P. J. Richardson & M. A. Wyke*

647 Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam: *A. N. Griffiths, D. M. Jones & A. Richens*

655 The effect of verapamil on antipyrine pharmacokinetics and metabolism in man: *D. Bach, R. Blevins, N. Kerner, M. Rubenfire & D. J. Edwards*

661 Sparteine oxidation polymorphism: a family study: *K. Brosen, S. V. Otton & L. F. Gram*

669 The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchoceriasis: *K. Awadzi, K. K. Adjepon-Yamoah, G. Edwards, M. L'E Orme & A. M. Breckenridge*

677 Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria: *R. E. Phillips, S. Looareesuwan, N. J. White, K. Silamut, S. Kietyinun & D. A. Warrell*

685 Inhibition of human gastric secretion by ICI 162, 846—a new histamine H_2-receptor antagonist: *J. A. Wilson, D. A. Johnston, J. Penston & K. G. Wormsley*

691 The effects of diabetes mellitus, exercise and single doses of biguanides upon lactate metabolism in man: *P. Fletcher, M. R. Hirji, S. Kuhn, L. Alexander & J. C. Mucklow*

701 Knowledge of and attitudes to medicines in the Southampton community: *S. Ridout, W. E. Waters & C. F. George*

Short report

713 Effect of nadolol on liver haemodynamics and function in patients with cirrhosis: *C. Merkel, D. Sacerdoti, G. F. Finucci, R. Zuin, G. Bazzerla, M. Bolognesi & A. Gatta*

Letter to the Editors

721 Ageing and platelet α_2-adrenoceptors: *C. Buckley, D. Curtin, T. Walsh & K. O'Malley*

Indexes

723 Author and subject indexes to Volume 21

Supplement 1 to Volume 21, 1986

α_1-Adrenoceptor blockade in hypertension: pharmacological and clinical profile of doxazosin

3S Introduction: *J. L. Reid & H. C. Davies*

Pharmacology of doxazosin

5S The pharmacological basis for the use of α_1-adrenoceptor antagonists in the treatment of essential hypertension: *M. J. Davey*

9S The α_1-adrenoceptor antagonist profile of doxazosin: preclinical pharmacology: *V. A. Alabaster & M. J. Davey*

19S The metabolism and kinetics of doxazosin in man, mouse, rat and dog: *B. Kaye, N. J. Cussans, J. K. Faulkner, D. A. Stopher & J. L. Reid*

27S Clinical pharmacological studies with doxazosin: *H. L. Elliott, P. A. Meredith, J. Vincent & J. L. Reid*

33S α-Adrenergic receptors in human blood vessels: *P. van Brummelen, K. Jie & P. A. van Zwieten*

41S Acute renal effects of doxazosin in man: *P. W. de Leeuw, P. N. van Es, R. de Bos & W. H. Birkenhäger*

45S Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise: *P. Lund-Johansen, P. Omvik & H. Haugland*

Clinical profile of doxazosin

55S A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension: *M. H. Frick, P. Halttunen, P. Himanen, M. Huttunen, P. Pörsti, T. Pitkäjärvi, L. Pöyhönen, M.-L. Pyykönen, P. Reinikainen, P. Salmela & M. Saraste*

63S Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol: *M. A. Baez, D. C. Garg, N. S. Jallad & D. J. Weidler*

69S Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension: *D. Torvik & H.-P. Madsbu*

77S Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins: *A. Lehtonen, P. Himanen, M. Saraste, K. Niittymäki & J. Marniemi*

83S The antihypertensive effects of doxazosin: a clinical overview: *D. A. Cox, J. P. Leader, J. A. Milson & W. Singleton*

91S Summary: *J. L. Reid & H. C. Davies*

Supplement 2 to Volume 21, 1986

Calcium antagonists and their future clinical potential

93S Preface

95S Introductory remarks: J. L. Reid

97S Calcium antagonists and their mode of action: an historical overview: *W. G. Nayler & J. S. Dillon*

109S The mechanism of action of calcium antagonists relative to their clinical applications: *B. N. Singh*

123S Salt and hypertension: *G. A. MacGregor*

129S The management of hypertension: *B. N. C. Prichard & C. W. I. Owens*

143S Once a day verapamil in essential hypertension: *F. B. Müller, H. R. Ha, H. Hotz, O. Schmidlin, F. Follath & F. R. Bühler*

149S Pharmacokinetics of conventional and slow-release verapamil: *F. Follath, H. R. Ha, E. Schuetz & F. Buhler*

155S Combination therapy with β-adrenoceptor blockers and calcium antagonists: *H. J. Dargie*

161S Calcium channel blockade: an alternative to diuretic therapy: *J. P. Nicholson, L. M. Resnick & J. Laragh*

165S Studies on verapamil in the treatment of essential hypertension: a review: *K. Midtbø, O. Hals, O. Lauve, J. van der Meer & L. Storstein*

173S Assessment of quality of life in cardiovascular therapy: *A. E. Fletcher & C. J. Bulpitt*

183S Verapamil in arrhythmia: *D. M. Krikler*

191S Verapamil in angina pectoris: *D. T. Kelly*

197S The Danish studies on verapamil in acute myocardial infarction: *The Danish Study Group on verapamil in myocardial infarction*